Nov 13, 2025 04:05PM
Sep 29, 2025 04:05PM
Sep 25, 2025 07:30AM
Sep 25, 2025 07:30AM
Feb 25, 2025 10:28AM
Feb 14, 2025 04:05PM
Dec 23, 2024 09:16AM Anebulo Pharmaceuticals (ANEB) Announces Positive Regulatory Update for Selonabant
Dec 23, 2024 09:15AM
Feb 13, 2024 04:05PM
Nov 14, 2023 04:05PM
Nov 8, 2023 04:01PM
Sep 20, 2023 04:29PM
Aug 30, 2023 08:00AM
Aug 21, 2023 08:00AM Anebulo Pharmaceuticals (ANEB) Reports Positive FDA Feedback on Path to Advance Phase 3 Clinical Development of ANEB-001
Aug 21, 2023 08:00AM
May 11, 2023 08:00AM
May 4, 2023 04:01PM
Mar 28, 2023 08:02AM
Mar 28, 2023 08:00AM
Mar 8, 2023 08:00AM
Feb 10, 2023 08:38AM  Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
Jan 9, 2023 08:00AM
Sep 26, 2022 07:00AM
Sep 26, 2022 07:00AM
Sep 9, 2022 08:00AM
Jul 5, 2022 06:01AM
Jul 5, 2022 06:00AM
Jun 23, 2022 04:00PM Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
May 24, 2022 04:00PM
May 24, 2022 04:00PM
Apr 1, 2022 07:00AM
Feb 11, 2022 08:00AM
Jan 4, 2022 07:01AM
Jan 4, 2022 07:00AM
Jan 3, 2022 07:00AM Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
Nov 12, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All